Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q2 2023 Earnings Conference Call August 1, 2023 8:30 AM ET
Company Participants
Luis Sanay - Head, Investor Relations
Dr. Jeffrey Dayno - President and CEO
Jeffrey Dierks - Chief Commercial Officer
Dr. Kumar Budur - Chief Medical Officer
Sandip Kapadia - Chief Financial Officer
Conference Call Participants
Alex Sklar - Raymond James
David Amsellem - Piper Sandler
Francois Brisebois - Oppenheimer
Graig Suvannavejh - Mizuho Securities
Jason Gerberry - Bank of America
Corinne Jenkins - Goldman Sachs
Charles Duncan - Cantor Fitzgerald
Operator
Good morning. My name is Todd, and I will be your conference operator today. At this time, I would like to welcome everyone to Harmony Biosciences Second Quarter 2023 Financial Results Conference Call. All participant lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference maybe recorded. [Operator Instructions]
I will now turn the call over to Luis Sanay, Head of Investor Relations. Please go ahead.
Luis Sanay
Thank you, Operator. Good morning, everyone. And thank you for joining us today as we review Harmony Biosciences second quarter 2023 financial results and provide a business update. Before we start, I encourage everyone to go to the Investors section of our website to find the materials that accompany our discussion today, including a reconciliation of our GAAP to non-GAAP financial measures. At this stage of our life cycle, we believe non-GAAP financial results better represent the underlying business performance.
Our speakers on today’s call are Dr. Jeffrey Dayno, President and CEO; Jeffrey Dierks, Chief Commercial Officer; Dr. Kumar Budur, our Chief Medical Officer; and Sandip Kapadia, Chief Financial Officer.
Moving on to slide two, as a reminder, we will be making forward-looking statements today, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, our actual results may differ materially and we undertake no obligation to update these statements even if circumstances change. We encourage you to consult the risk factors referenced in our SEC filings for additional details.
I would now like to turn the call over to Dr. Jeffrey Dayno. Jeff?
Dr. Jeffrey Dayno
Thank you, Luis. And thank you everyone for joining our conference call today and for your interest in Harmony. Before I comment on our strong second quarter performance, which is reflective of our focused execution and operational excellence, I want to highlight why Harmony continues to be a growth story and outline the key elements driving our growth.